Tre-O2-02 - Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data

Abstract

Background: In Europe, it is estimated that the annual incidence of cutaneous T-cell lymphoma (CTCL) is approximately 52 new cases per million, affecting around 240 people per million at any one time [1]. Mycosis fungoides (MF) and Sézary syndrome (SS) are rare, debilitating, and potentially life-threatening subtypes of CTCL [2,3]. A recent systematic review and meta-analysis of 16,953 patients globally found that MF and SS represented 62% and 3% of CTCLs, respectively [4]. In the phase 3 MAVORIC trial, mogamulizumab (KW-0761, Poteligeo®)* showed significant improvements over vorinostat in terms of progression-free survival, overall response, and patient-reported quality-of-life [5].